Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Travoprost/timolol

Drug Profile

Travoprost/timolol

Alternative Names: 0.004% travoprost/0.5% timolol; DuoTrav; DuoTrav APS; DuoTrav® PQ; DuoTrav™ BAK; Extravan; Timolol/travoprost; Travoprost + Timolol Fixed Combination; TTFC

Latest Information Update: 15 Apr 2019

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alcon
  • Developer Alcon; Novartis
  • Class Antiglaucomas; Antihypertensives; Propanolamines; Prostaglandins; Thiadiazoles
  • Mechanism of Action Beta adrenergic receptor antagonists; Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glaucoma

Most Recent Events

  • 09 Apr 2019 Novartis completed the spin-off of Alcon eye care devices business
  • 27 Jan 2017 Novartis has patent protection for travoprost/timolol in Europe and Japan (Novartis 20-F filed in 2017)
  • 13 Apr 2015 No recent reports on development identified - Preregistration for Glaucoma in USA (Ophthalmic)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top